In Vitro Analysis and Dynamic Modeling of SARS-CoV-2 Infection Inhibition by Sigma-1 Receptor Antagonist PB28
Bulletin of Mathematical Biology · 2026
DOI: 10.1007/s11538-026-01642-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Mathematical Biology, 2026. Verfasst von Bartek Lisowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. Hauptthemen laut MEDLINE: Receptors, sigma, SARS-CoV-2, Models, Biological, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Karlova v Praze, International Visegrad Fund, Uniwersytet Jagielloński w Krakowie.
Abstract (Originalsprache)
Understanding how antiviral compounds modulate infection dynamics is essential for the assessment and optimization of therapeutic candidates. Here, we combined mechanistic modeling with in vitro experimental data to quantify the antiviral efficacy of PB28, a high-affinity sigma receptor ligand, against SARS-CoV-2 infection in A549-ACE2 cells. Viral load measurements from both time-course and end-point assays across multiple PB28 concentrations were used to calibrate a viral dynamics model incorporating a Hill-type inhibitory function. This approach enabled the estimation of key viral life-cycle parameters – including infection rate, latent and infectious phase durations, and virus production rate – alongside parameters characterizing the action of PB28. Despite relying on minimal experimental input, characteristic of early-stage drug repurposing screens, the model provided accurate fits and robust parameter estimates. Our analysis shows that PB28 reduces viral production in a concentration-dependent manner with near-linear cooperativity and demonstrates how time-resolved modeling facilitates post hoc inference of an apparent, time-dependent $$\text {IC}_{50}$$ IC 50 . Notably, estimates of $$\text {IC}_{50}$$ IC 50 from time-resolved infections were approximately twofold higher than those obtained from end-point assays. Overall, these results demonstrate that dynamic modeling facilitates more targeted characterization of pharmacodynamic parameters, including $$\text {IC}_{50}$$ IC 50 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.
- Institut Pasteur, Viral Populations and Pathogenesis Unit, Department of Virology, Paris, F-75015, France.
- A*STAR Infectious Diseases Labs (A*STAR ID Labs), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
- Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
- Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona, 4, 70125, Bari, Italy.
Förderung
- Univerzita Karlova v Praze
- International Visegrad Fund
- Uniwersytet Jagielloński w Krakowie
- Ministerstvo Školství, Mládeže a Tělovýchovy
Zitieren
APA
Lisowski, B., V Rezelj, V., Vignuzzi, M., Abate, C., & Bernhauerová, V. (2026). In Vitro Analysis and Dynamic Modeling of SARS-CoV-2 Infection Inhibition by Sigma-1 Receptor Antagonist PB28. Bulletin of Mathematical Biology. https://doi.org/10.1007/s11538-026-01642-2
Vancouver
Lisowski B, V Rezelj V, Vignuzzi M, Abate C, Bernhauerová V. In Vitro Analysis and Dynamic Modeling of SARS-CoV-2 Infection Inhibition by Sigma-1 Receptor Antagonist PB28. Bulletin of Mathematical Biology. 2026. doi:10.1007/s11538-026-01642-2
BibTeX
@article{Lisowski2026,
author = {Lisowski, Bartek and V Rezelj, Veronica and Vignuzzi, Marco and Abate, Carmen and Bernhauerová, Veronika},
title = {In Vitro Analysis and Dynamic Modeling of SARS-CoV-2 Infection Inhibition by Sigma-1 Receptor Antagonist PB28},
journal = {Bulletin of Mathematical Biology},
year = {2026},
doi = {10.1007/s11538-026-01642-2}
}
EUVIMED